Share:
Children with HIV-associated TB have few antiretroviral therapy options. A study, published in The Lancet HIV, evaluated the safety and pharmacokinetics of dolutegravir twice-daily dosing in children receiving rifampicin for HIV-associated TB.
Access the full study here.
For more TB news, check out the latest edition of the TB Online Weekly Newsletter (#25, 21 July 2022).
Source : The Lancet HIV
Related HIV and Co-Infections News
-
Florida International University: HIV disrupts lung “clock,” raising COPD and emphysema risk
-
[Report] Physicians for Human Rights: Trump administration foreign policy approach to South Africa wastes billions of dollars, imperils global health
-
ESCMID: HIV treatment reduces accelerated biological aging by nearly four years, landmark study shows
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.